Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity

Nature

Volumn 441, Issue 7090, 2006, Pages 239-243

  Roberts, Diane M ^a   Nanda, Anjali ^a   Havenga, Menzo J E ^b   Abbink, Peter ^a   Lynch, Diana M ^a   Ewald, Bonnie A ^a   Liu, Jinyan ^a   Thorner, Anna R ^a   Swanson, Patricia E ^a   Gorgone, Darci A ^a   Lifton, Michelle A ^a   Lemckert, Angelique A C ^b   Holterman, Lennart ^b   Chen, Bing ^a   Dilraj, Athmanundh ^c   Carville, Angela ^a   Mansfield, Keith G ^a   Goudsmit, Jaap ^b   Barouch, Dan H ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b CRUCELL HOLLAND BV   (Netherlands)

^c SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODIES; BIOMEDICAL ENGINEERING; DISEASES; GENES; PROTEINS; VACCINES; VIRUSES;

ANTI-VECTOR IMMUNITY; IMMUNOGENICITY; VECTOR-BASED VACCINES; VIRAL SURFACE PROTEINS;

IMMUNOLOGY;

ADENOVIRUS VECTOR; CAPSID PROTEIN; EPITOPE; GAG PROTEIN; HEXON PROTEIN; MEMBRANE PROTEIN; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANTIBODY; IMMUNITY; PATHOGEN; PROTEIN; VACCINATION; VIRAL DISEASE;

ADENOVIRUS 5; ARTICLE; CHIMERA; GENE DELIVERY SYSTEM; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNITY; IMMUNOGENICITY; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; RHESUS MONKEY; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS CAPSID; VIRUS GENE; VIRUS IMMUNITY; VIRUS REPLICATION;

ADENOVIRIDAE; HUMAN ADENOVIRUS TYPE 5; HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA MULATTA; MIRIDAE; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 33646586362     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature04721     Document Type: Article

References (22)

1. Shiver, J. W. et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415, 331-335 (2002).
2. Sullivan, N. J. et al. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 424, 681-684 (2003).
3. Shiver, J. W. & Emini, E. A. Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. Annu. Rev. Med. 55, 355-372 (2004).
4. Vogels, R. et al. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell interaction and bypass of preexisting adenovirus immunity. J. Virol. 77, 8263-8271 (2003).
5. Kostense, S. et al. Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector. AIDS 18, 1213-1216 (2004).
6. Sumida, S. M. et al. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J. Immunol. 174, 7179-7185 (2005).
7. Barouch, D. H. et al. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J. Immunol. 172, 6290-6297 (2004).
8. Casimiro, D. R. et al. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J. Virol. 77, 6305-6313 (2003).
9. Youil, R. et al. Hexon gene switch strategy for the generation of chimeric recombinant adenovirus. Hum. Gene Ther. 13, 311-320 (2002).
10. Gall, J. G., Crystal, R. G. & Falck-Pedersen, E. Construction and characterization of hexon-chimeric adenoviruses: specification of adenovirus serotype. J. Virol. 72, 10260-10264 (1998).
11. Crawford-Miksza, L. & Schnurr, D. P. Analysis of 15 adenovirus hexon proteins reveals the location and structure of seven hypervariable regions containing serotype-specific residues. J. Virol. 70, 1836-1844 (1996).
12. Athappilly, F. K., Murali, R., Rux, J. J., Cai, Z. & Burnett, R. M. The refined crystal structure of hexon, the major coat protein of adenovirus type 2, at 2.9 Å resolution. J. Mol. Biol. 242, 430-455 (1994).
13. Rux, J. J., Kuser, P. R. & Burnett, R. M. Structural and phylogenetic analysis of adenovirus hexons by use of high-resolution x-ray crystallographic, molecular modeling, and sequence-based methods. J. Virol. 77, 9553-9566 (2003).
14. Jones, T. A., Zou, J. Y., Cowan, S. W. & Kjeldgaard, M. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr. A 47, 110-119 (1991).
15. Kraulis, P. J. MOLSCRIPT: A program to produce both detailed and schematic plots of protein structures. J. Appl. Crystallogr. 24, 946-950 (1991).
16. Sprangers, M. C. et al. Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors. J. Clin. Microbiol. 41, 5046-5052 (2003).
17. Pitcher, C. J. et al. Development and homeostasis of T cell memory in rhesus macaque. J. Immunol. 168, 29-43 (2002).
18. Gahery-Segard, H. et al. Immune response to recombinant capsid proteins of adenovirus in humans: antifiber and anti-penton base antibodies have a synergistic effect on neutralizing activity. J. Virol. 72, 2388-2397 (1998).
19. Hong, S. S., Habib, N. A., Franqueville, L., Jensen, S. & Boulanger, P. A. Identification of adenovirus (Ad) penton base neutralizing epitopes by use of sera from patients who had received conditionally replicative Ad (Addl1520) for treatment of liver tumors. J. Virol. 77, 10366-10375 (2003).
20. Wohlfart, C. Neutralization of adenoviruses: kinetics, stoichiometry, and mechanisms. J. Virol. 62, 2321-2328 (1988).
21. Havenga, M. J. et al. Improved adenovirus vectors for infection of cardiovascular tissues. J. Virol. 75, 3335-3342 (2001).
22. Nanda, A. et al. Immunogenicity of recombinant fiber-chimeric adenovirus serotype 35 vector-based vaccines in mice and rhesus monkeys. J. Virol. 79, 14161-14168 (2005).